3,4-Dihydro-3-oxo-4-β-D-ribofuranosyl-2-pyrazinecarboxamide

Cat. No.: HY-152604: FAQs
Data Sheet Handling Instructions Technical Support

3,4-Dihydro-3-oxo-4-β-D-ribofuranosyl-2-pyrazinecarboxamide is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.

For research use only. We do not sell to patients.

3,4-Dihydro-3-oxo-4-β-D-ribofuranosyl-2-pyrazinecarboxamide Chemical Structure

CAS No. : 356782-84-8

Size	Stock	Quantity
5 mg	Get quote 3 - 4 weeks 2 - 3 weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
10 mg	Get quote
50 mg	Get quote

Synthetic products have potential research and development risk.

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
CV-1	EC₅₀	> 100 μg/mL Compound: T-1106	Antiviral activity against YFV infected in african green monkey CV1 cells assessed as reduction in cytopathic effect after 6 days Antiviral activity against YFV infected in african green monkey CV1 cells assessed as reduction in cytopathic effect after 6 days	[PMID: 17420215]
MDCK	CC₅₀	> 250 μM Compound: T-1105-ribonucleoside	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 3 days by formazan-based MTS assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 3 days by formazan-based MTS assay	[PMID: 29906392]
MDCK	CC₅₀	> 250 μM Compound: T-1105-ribonucleoside	Cytotoxicity against HGPRT deficient 6-thioguanine-resistant MDCK cells assessed as reduction in cell viability after 3 days by formazan-based MTS assay Cytotoxicity against HGPRT deficient 6-thioguanine-resistant MDCK cells assessed as reduction in cell viability after 3 days by formazan-based MTS assay	[PMID: 29906392]
Vero	EC₅₀	> 100 μg/mL Compound: T-1106	Antiviral activity against YFV infected in african green monkey Vero cells assessed as reduction in cytopathic effect after 6 days Antiviral activity against YFV infected in african green monkey Vero cells assessed as reduction in cytopathic effect after 6 days	[PMID: 17420215]
Vero	CC₅₀	> 4000 μM Compound: T-1106	Cytotoxicity against African green monkey Vero cells by luciferase-based cell viability assay Cytotoxicity against African green monkey Vero cells by luciferase-based cell viability assay	[PMID: 18955536]
Vero	EC₅₀	1080 μM Compound: T-1106	Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect by microscopic analysis Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect by microscopic analysis	[PMID: 18955536]
Vero	EC₅₀	1800 μM Compound: T-1106	Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect after 2 hrs by NR dye uptake assay Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect after 2 hrs by NR dye uptake assay	[PMID: 18955536]
Vero	EC₅₀	2630 μM Compound: T-1106	Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect by luciferase reporter gene assay Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect by luciferase reporter gene assay	[PMID: 18955536]

Molecular Weight

271.23

Formula

C₁₀H₁₃N₃O₆

CAS No.

356782-84-8

SMILES

OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C=CN=C(C(N)=O)C2=O)O1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. [Content Brief]